Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor

Blood. 1995 Nov 1;86(9):3500-6.

Abstract

Granzyme B and perforin are cytoplasmic granule-associated proteins used by cytotoxic T lymphocytes and natural killer (NK) cells to kill their targets. However, granzyme B gene expression has also been detected in a non-cytotoxic hematopoietic murine multipotent stem cell line, FDCP-Mix. The objective of the present study was to investigate whether granzyme B and perforin could be expressed in human hematopoietic CD34+ cells and if present, discover what their physiologic relevance could be. The primitive CD34+ human cell line KG1a was investigated first and was found to express granzyme B and perforin. Highly purified hematopoietic stem/progenitor cells were then selected using the CD34 surface antigen as marker. Steady-state bone marrow (BM) CD34+ cells did not contain these proteins. Peripheral blood (PB) CD34+ cells, which had been induced to circulate, were also analyzed. After chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF) treatment, CD34+ cells strongly expressed mRNAs and proteins of granzyme B and perforin. In contrast, CD34+ cells mobilized by G-CSF alone were negative. Western blot analysis further showed that granzyme B and perforin proteins were identical in CD34+ cells and activated PBLs. Such proteins might be implicated in the highly efficient migration of CD34+ stem/progenitor cells from BM to PB after CT and G-CSF treatment. The cellular adhesion mechanisms involved in the BM homing of CD34+ cells are disrupted at least temporarily after CT. The Asp-ase proteolytic activity of granzyme B on extracellular matrix proteins could be used by progenitor cells for their rapid detachment from BM stromal cells and perforin might facilitate their migration across the endothelial cell barrier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD34
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow / drug effects
  • Bone Marrow Cells*
  • Cell Adhesion
  • Cell Line
  • Cell Movement
  • Cyclophosphamide / pharmacology
  • Gene Expression Regulation / drug effects*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Granzymes
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / metabolism*
  • Humans
  • In Situ Hybridization
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin / blood
  • Lymphoma, Non-Hodgkin / drug therapy
  • Membrane Glycoproteins / biosynthesis*
  • Membrane Glycoproteins / genetics
  • Multiple Myeloma / blood
  • Multiple Myeloma / drug therapy
  • Perforin
  • Pore Forming Cytotoxic Proteins
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Serine Endopeptidases / biosynthesis*
  • Serine Endopeptidases / genetics
  • Tumor Cells, Cultured

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Membrane Glycoproteins
  • Pore Forming Cytotoxic Proteins
  • Perforin
  • Granulocyte Colony-Stimulating Factor
  • Cyclophosphamide
  • GZMB protein, human
  • Granzymes
  • Serine Endopeptidases